Related Experiment Video
Updated: Jun 3, 2025
10:19
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
1.2K
Bispecific Antibodies for Lymphoid Malignancy Treatment
Matteo Bisio1, Luca Legato1, Filippo Fasano1
1Hematology Division, A.O.U. Città della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy.
Cancers
|January 11, 2025
Summary
Bispecific antibodies (BsAbs) offer a promising new treatment for relapsed/refractory B-cell non-Hodgkin lymphomas. These off-the-shelf therapies show significant activity and manageable safety in heavily pretreated patients.
Area of Science:
- Hematology
- Immunotherapy
- Oncology
Background:
- Immunotherapies have revolutionized B-cell non-Hodgkin lymphomas (B-NHLs) treatment over the past 20 years.
- Advances include CAR-T therapy, antibody-drug conjugates, and bispecific antibodies (BsAbs).
- These therapies are crucial for treating diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).
Purpose of the Study:
- To review recent and ongoing bispecific antibody (BsAb) trials in relapsed/refractory (R/R) B-NHL and Hodgkin lymphoma.
- To summarize single-agent results, combination therapies, safety data, and novel BsAb constructs.
- To provide an updated overview of BsAb efficacy and safety in lymphoma treatment.
Main Methods:
- Review of completed and ongoing clinical trials involving bispecific antibodies (BsAbs).
- Analysis of published data on single-agent BsAb therapy.
- Evaluation of emerging combination strategies involving BsAbs.
- Assessment of safety profiles and toxicity data from BsAb trials.
Main Results:
- Bispecific antibodies (BsAbs) demonstrate significant single-agent activity in heavily pretreated B-NHL.
- Emerging combinations of BsAbs show potential for enhanced therapeutic effects.
- Novel BsAb constructs targeting antigens like CD19 × CD3 and CD30 × CD3 are under investigation.
- BsAbs exhibit a manageable toxicity profile in patients with R/R B-NHL.
Conclusions:
- Bispecific antibodies (BsAbs) represent a novel class of "off-the-shelf" T-cell-redirecting therapies.
- BsAbs are a highly promising therapeutic option for lymphoma patients, particularly those with R/R B-NHL.
- Ongoing research is exploring new antigen targets and combinations to further optimize BsAb therapy.
Related Concept Videos
01:27Tumor Immunotherapy
472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:31Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K
01:20Special Features of Adaptive Immunity
744
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
744